Sumitovant Biopharma Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Sumitovant Biopharma's estimated annual revenue is currently $9.9M per year.
- Sumitovant Biopharma's estimated revenue per employee is $155,000
- Sumitovant Biopharma has 64 Employees.
- Sumitovant Biopharma grew their employee count by 56% last year.
- Sumitovant Biopharma currently has 1 job openings.
What Is Sumitovant Biopharma?
Sumitovant is a global biopharma company with offices in New York and London. It is the parent company of five biopharmaceutical companies: Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and Spirovant Sciences. Our companies have a robust pipeline of innovative drug treatments targeting a broad range of diseases. ￃﾢ￢ﾂﾬￂﾢ Sumitovantￃﾢ￢ﾂﾬ￢ﾄﾢs Digital Innovation approach integrates key skill sets, data sets and analytic tools to provide real answers to pharmaￃﾢ￢ﾂﾬ￢ﾄﾢs most critical questions. With our tech-enabled approach to drug discovery, development and commercialization, we remove friction and accelerate every aspect of the process to bring promising new compounds to market. Sumitovant is wholly owned by Sumitomo Dainippon Pharma. Together, the Sumitomo Dainippon Pharma group of companies closely collaborate to expedite the discovery, development, and commercialization of truly innovative treatments. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes and shareholder return.keywords:N/A